Literature DB >> 14656908

Recommendations of the National Heart, Lung, and Blood Institute Nanotechnology Working Group.

Denis B Buxton1, Stephen C Lee, Samuel A Wickline, Mauro Ferrari.   

Abstract

Recent rapid advances in nanotechnology and nanoscience offer a wealth of new opportunities for diagnosis and therapy of cardiovascular, pulmonary, and hematologic diseases and sleep disorders. To review the challenges and opportunities offered by these nascent fields, the National Heart, Lung, and Blood Institute convened a Working Group on Nanotechnology. Working Group participants discussed the various aspects of nanotechnology and its applications to heart, lung, blood, and sleep (HLBS) diseases. This report summarizes their discussions according to scientific opportunities, perceived needs and barriers, specific disease examples, and recommendations on facilitating research in the field. An overarching recommendation of the Working Group was to focus on translational applications of nanotechnology to solve clinical problems. The Working Group recommended the creation of multidisciplinary research centers capable of developing applications of nanotechnology and nanoscience to HLBS research and medicine. Centers would also disseminate technology, materials, and resources and train new investigators. Individual investigators outside these centers should be encouraged to conduct research on the application of nanotechnology to biological and clinical problems. Pilot programs and developmental research are needed to attract new investigators and to stimulate creative, high-impact research. Finally, encouragement of small businesses to develop nanotechnology-based approaches to clinical problems was considered important.

Entities:  

Mesh:

Year:  2003        PMID: 14656908     DOI: 10.1161/01.CIR.0000096493.93058.E8

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  12 in total

1.  Nanoparticle-induced platelet aggregation and vascular thrombosis.

Authors:  Anna Radomski; Paul Jurasz; David Alonso-Escolano; Magdalena Drews; Maria Morandi; Tadeusz Malinski; Marek W Radomski
Journal:  Br J Pharmacol       Date:  2005-11       Impact factor: 8.739

2.  Blood compatible carbon nanotubes--nano-based neoproteoglycans.

Authors:  Saravanababu Murugesan; Tae-Joon Park; Hoichang Yang; Shaker Mousa; Robert J Linhardt
Journal:  Langmuir       Date:  2006-04-11       Impact factor: 3.882

Review 3.  Pulmonary applications and toxicity of engineered nanoparticles.

Authors:  Jeffrey W Card; Darryl C Zeldin; James C Bonner; Earle R Nestmann
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-07-18       Impact factor: 5.464

4.  Cardiovascular nanomedicine: a posse ad esse.

Authors:  Biana Godin; Mauro Ferrari
Journal:  Methodist Debakey Cardiovasc J       Date:  2012-01

5.  Patent ductus arteriosus in premature infants: A never-closing act.

Authors:  Bernard Thébaud; Thierry Lacaze-Mazmonteil
Journal:  Paediatr Child Health       Date:  2010-05       Impact factor: 2.253

Review 6.  Native and Reconstituted Plasma Lipoproteins in Nanomedicine: Physicochemical Determinants of Nanoparticle Structure, Stability, and Metabolism.

Authors:  Henry J Pownall; Corina Rosales; Baiba K Gillard; Mauro Ferrari
Journal:  Methodist Debakey Cardiovasc J       Date:  2016-09

Review 7.  Role and implications of nanodiagnostics in the changing trends of clinical diagnosis.

Authors:  Khalid Khalaf Alharbi; Yazeed A Al-Sheikh
Journal:  Saudi J Biol Sci       Date:  2013-11-19       Impact factor: 4.219

Review 8.  Nanodevices in diagnostics.

Authors:  Ye Hu; Daniel H Fine; Ennio Tasciotti; Ali Bouamrani; Mauro Ferrari
Journal:  Wiley Interdiscip Rev Nanomed Nanobiotechnol       Date:  2011 Jan-Feb

Review 9.  Drug delivery and nanoparticles:applications and hazards.

Authors:  Wim H De Jong; Paul J A Borm
Journal:  Int J Nanomedicine       Date:  2008

10.  Lost in Translation: Obstacles to Translational Medicine.

Authors:  Stacey P Mankoff; Christian Brander; Soldano Ferrone; Francesco M Marincola
Journal:  J Transl Med       Date:  2004-05-18       Impact factor: 5.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.